---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-029177"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:16:36.659753+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics receives Nasdaq delisting notice; additional $350K note from 3i

## Summary
- Nasdaq notified the company on April 11, 2023 that it failed to meet extension terms for minimum $10M equity rule; delisting set for April 20 unless appeal.
- Company reported stockholders' equity of ~$8.0M as of June 30, 2022, below the $10M continued listing requirement.
- Entered first amendment allowing additional note purchases from 3i, LP; on April 11, 3i purchased a $350,000 secured promissory note.
- Total principal outstanding under the notes is $2,666,640; new notes bear 5% interest, mature Jan 1, 2024, and are secured by all assets.
- Company intends to appeal the delisting determination to Nasdaq.

## SEC filing metadata
- accession: 0001213900-23-029177
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 3.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/ea176859-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-029177
- JSON: https://secwatch.observer/filing/0001213900-23-029177.json
- Plain text: https://secwatch.observer/filing/0001213900-23-029177.txt

## Key facts
- Debt Financings
  Allarity Therapeutics, Inc. incurred convertible notes of $350,000 with 3i, LP at 5% per annum maturing January 1, 2024.
  - Instrument: convertible notes
  - Principal: $350,000
  - Counterparty: 3i, LP
  - Rate: 5% per annum
  - Maturity: January 1, 2024
  - Event: incurrence
  source text: On April 11, 2023, 3i purchased an additional note for an aggregate amount of $350,000, which purchase price was paid for in cash. Each note issued under the Purchase Agreement matures on January 1, 2024, carries an interest rate of at 5% per annum, and is secured by all of the Company’s assets pursuant to a security agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm
- Listing & Compliance Notices
  Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: April 11, 2023, we received notification from the Nasdaq Listing Qualifications staff that it has determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Form 8-K by the April 10, 2023 deadline, evidencing compliance with the Rule. As a result, the Company’s securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of such determination, trading of the Company’s Common Stock will be suspended at the opening of business on April 20, 20
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. amended First Amendment to the Secured Note Purchase Agreement with 3i, LP valued at aggregate principal amount of $2,666,640 (effective 2023-04-10).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: 3i, LP
  - Value: aggregate principal amount of $2,666,640
  - Effective: 2023-04-10
  source text: Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) entered into a First Amendment to the Secured Note Purchase Agreement dated April 10, 2023 (the “First Amendment”) with 3i, LP (“3i”), the sole holder of our Series A Convertible Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.